摘要
At the recent 2022 American Society of Clinical Oncology(ASCO)annual meeting,the latest progress was presented in clinical trials of various therapeutic modalities for adult soft tissue sarcoma(STS),including chemotherapy,targeted therapy,anti-immune checkpoint immunotherapy,and multiple combination treatments(Table 1).Generally,the development of clinical treatments for STS is relatively slow,owing to the complex pathological subtypes of sarcoma and their heterogeneous biological behaviors.Here,we briefly summarize updates from this year’s ASCO meeting and discuss the future therapeutic perspectives for unspecific STS.
作者简介
Jilong Yang,contributed equally to this work;Yu Xu,contributed equally to this work;Correspondence to:Jilong Yang,E-mail:yangjilong@tjmuch.com;Correspondence to:Yun Yang,E-mail:yydocter@sina.com,ORCID ID:https://orcid.org/0000-0001-5162-3740。
